{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:25:17Z","timestamp":1784366717921,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10620-025-09538-2","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:33:11Z","timestamp":1762590791000},"page":"1416-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Patients with Ulcerative Proctitis: A Global Survey"],"prefix":"10.1007","volume":"71","author":[{"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Sequier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Gustavo","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"9538_CR1","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1136\/gutjnl-2016-311970","volume":"66","author":"A Hochart","year":"2017","unstructured":"Hochart A, Gower-Rousseau C, Sarter H et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut 2017;66:1912\u20131917. https:\/\/doi.org\/10.1136\/gutjnl-2016-311970.","journal-title":"Gut"},{"key":"9538_CR2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1080\/00365521.2018.1524026","volume":"53","author":"JM Huguet","year":"2018","unstructured":"Huguet JM, Ferrer-Barcel\u00f3 L, Su\u00e1rez P et al. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol 2018;53:1286\u20131290. https:\/\/doi.org\/10.1080\/00365521.2018.1524026.","journal-title":"Scand J Gastroenterol"},{"key":"9538_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab218","author":"B Caron","year":"2021","unstructured":"Caron B, Sandborn WJ, Panaccione R et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis. 2021. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab218.","journal-title":"J Crohns Colitis"},{"key":"9538_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/2050640620941345","volume":"8","author":"E Dubois","year":"2020","unstructured":"Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United Eur Gastroenterol J. 2020;8:933\u2013941. https:\/\/doi.org\/10.1177\/2050640620941345.","journal-title":"United Eur Gastroenterol J."},{"key":"9538_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/gutjnl-2021-324108","volume":"70","author":"B Caron","year":"2021","unstructured":"Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut. 2021;70:1203\u20131209. https:\/\/doi.org\/10.1136\/gutjnl-2021-324108.","journal-title":"Gut."},{"key":"9538_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cgh.2019.05.060","volume":"18","author":"G Pineton de Chambrun","year":"2020","unstructured":"Pineton de Chambrun G, Amiot A, Bouguen G et al. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2020;18:620\u2013627. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.060.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9538_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.dld.2016.12.001","volume":"49","author":"AL Mallet","year":"2017","unstructured":"Mallet AL, Bouguen G, Conroy G et al. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2017;49:280\u2013285. https:\/\/doi.org\/10.1016\/j.dld.2016.12.001.","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver."},{"key":"9538_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1365-2036.2010.04293.x","volume":"31","author":"G Bouguen","year":"2010","unstructured":"Bouguen G, Roblin X, Bourreille A et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31:1178\u20131185. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04293.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"9538_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet Lond Engl. 2023;401:1159\u20131171. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"Lancet Lond Engl."},{"key":"9538_CR10","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","volume":"18","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Dubinsky MC, Sands BE et al. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. J Crohns Colitis. 2024;18:1270\u20131282. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae038.","journal-title":"J Crohns Colitis."},{"key":"9538_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S2468-1253(24)00386-8","volume":"10","author":"BE Sands","year":"2025","unstructured":"Sands BE, Panaccione R, D\u2019Haens G et al. Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025;10:210\u2013221. https:\/\/doi.org\/10.1016\/S2468-1253(24)00386-8.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9538_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.032","author":"B Caron","year":"2022","unstructured":"Caron B, Abreu MT, Siegel CA et al. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.032.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"9538_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.14309\/ajg.0000000000001685","volume":"117","author":"JA Sninsky","year":"2022","unstructured":"Sninsky JA, Barnes EL, Zhang X, Long MD. Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. Am J Gastroenterol. 2022;117:769\u2013776. https:\/\/doi.org\/10.14309\/ajg.0000000000001685.","journal-title":"Am J Gastroenterol."},{"key":"9538_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.cgh.2023.02.029","volume":"21","author":"B Caron","year":"2023","unstructured":"Caron B, Ghosh S, Danese S, Peyrin-Biroulet L. Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21:1403-1413.e27. https:\/\/doi.org\/10.1016\/j.cgh.2023.02.029.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9538_CR15","doi-asserted-by":"publisher","unstructured":"Steinsb\u00f8 \u00d8, Aasprong OG, Aabakken L, Karlsen LN, Grimstad T. 2025. Fecal Calprotectin Correlates with Disease Extent but Remains a Reliable Marker of Mucosal Healing in Ulcerative Colitis. Am J Gastroenterol https:\/\/doi.org\/10.14309\/ajg.0000000000003339","DOI":"10.14309\/ajg.0000000000003339"},{"key":"9538_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf044","author":"EY Liu","year":"2025","unstructured":"Liu EY, An A, Khan S et al. The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izaf044.","journal-title":"Inflamm Bowel Dis"},{"key":"9538_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis."},{"key":"9538_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024;167:1307\u20131343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001.","journal-title":"Gastroenterology."},{"key":"9538_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/BF01295733","volume":"38","author":"RG Farmer","year":"1993","unstructured":"Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993;38:1137\u20131146. https:\/\/doi.org\/10.1007\/BF01295733.","journal-title":"Dig Dis Sci"},{"key":"9538_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae266","author":"A Miyazawa","year":"2024","unstructured":"Miyazawa A, Nambu R, Shimizu H et al. Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis A Multicenter Cohort Study. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae266.","journal-title":"Inflamm Bowel Dis"},{"key":"9538_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.18133","volume":"60","author":"R Ferreiro-Iglesias","year":"2024","unstructured":"Ferreiro-Iglesias R, Porto Silva S, Mar\u00edn S et al. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry. Aliment Pharmacol Ther. 2024;60:604\u2013612. https:\/\/doi.org\/10.1111\/apt.18133.","journal-title":"Aliment Pharmacol Ther."},{"key":"9538_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/14712598.2024.2369189","volume":"24","author":"D De Deo","year":"2024","unstructured":"De Deo D, Dal Buono A, Gabbiadini R et al. Management of proctitis in ulcerative colitis and the place of biological therapies. Expert Opin Biol Ther. 2024;24:443\u2013453. https:\/\/doi.org\/10.1080\/14712598.2024.2369189.","journal-title":"Expert Opin Biol Ther."},{"key":"9538_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cgh.2023.06.023","volume":"22","author":"P Lemmens","year":"2024","unstructured":"Lemmens P, Louis E, Van Moerkercke W et al. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22:154-163.e3. https:\/\/doi.org\/10.1016\/j.cgh.2023.06.023.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9538_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/ibd\/izae215","volume":"31","author":"RS Dalal","year":"2025","unstructured":"Dalal RS, Clarke LM, Carlin A, Cabral H, Allegretti JR. Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis. Inflamm Bowel Dis. 2025;31:1174\u20131177. https:\/\/doi.org\/10.1093\/ibd\/izae215.","journal-title":"Inflamm Bowel Dis."},{"key":"9538_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S2468-1253(25)00108-6","volume":"10","author":"AW Nguyen","year":"2025","unstructured":"Nguyen AW, Srinivasan AR, Lai M, Schildkraut T, Vasudevan A. Inclusion of patients with isolated ulcerative proctitis in clinical trials. Lancet Gastroenterol Hepatol. 2025;10:504. https:\/\/doi.org\/10.1016\/S2468-1253(25)00108-6.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09538-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09538-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:42:55Z","timestamp":1777970575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09538-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["9538"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09538-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BC has received lecture and\/or consulting fees from AbbVie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly, Nordic Pharma, Pfizer, and Takeda. LS reports no conflict of interest. AD reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis, and end-point committees from Abivax, AbbVie, Bristol Myers Squibb, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Alfasigma, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Sandoz, Stada, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Alfasigma, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Streamed-Up, Takeda, Tillotts, and Vifor Pharma; and payment for manuscript preparation from Abbvie, Falk Foundation, J&J, Takeda, Thieme, and UniMed Verlag. SG has received lectures and advisory committes for Janssen, AbbVie, and Takeda. AH served as consultant, advisory board member or speaker for AbbVie, Abivax, Arena, Atlantic, AstraZeneca, Bristol Myers Squibb, Celgene, Celltrion, Falk, Galapagos, GSK, Eli Lilly, Janssen, Johnson & Johnson, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Roche, Shire, and Takeda. VJ has received has received consulting\/advisory board fees from AbbVie, Alimentiv Inc. Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker\u2019s fees from, AbbVie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. TK served as an advisory board member, consultant, or speaker for AbbVie, Alfresa Pharma, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Kayaku, Pfizer, Sanofi, Sekisui, Takeda, and Zeria Pharmaceutical and has received research funding from AbbVie, Alfresa Pharma, Bristol Myers Squibb, EA Pharma, Gilead Sciences, Helmsley Charitable Trust, Kyorin Pharmaceutical, Miyarisan, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Samsung, Takeda, and Zeria Pharmaceutical. PGK received speaking and consultancy honorarium from Abbvie, Johnson and Johnson, Pfizer, Takeda, Celltrion and Sanofi. He also received scientific grants from Takeda and Pfizer and did clinical research for Lilly, Ventyx, Roche and Takeda. PL has been a speaker and\/or advisory board member: AbbVie, Amgen, Celltrion, Ferring, Fresenius Kabi, Gilead, Johnson & Johnson, Eli Lilly, Organon, Pharmacosmos, Pendopharm, Pfizer, Roche, Sandoz, Sanofi, and Takeda and has received unrestricted research grant: Gilead, Pfizer, and Takeda. EL received research grant: Janssen, Pfizer, Ferring, Falk, AbbVie, and Takeda; educational grant: AbbVie, Janssen, Fresenius Kabi, and Takeda; speaker fees: AbbVie, Falk, Ferring, Janssen, Pfizer, Galapagos, BMS, and Takeda; advisory board: AbbVie, Celgene, Ferring, Janssen, BMS, Pfizer, Takeda, Galapagos, Arena, and Eli Lilly; and consultant: AbbVie, Biokuris, Aboleris, and Thabor. FM received lectures fees from AbbVie, Arena, Biogen, Bristol Myers Squibb, Falk, Ferring, Hospira, Janssen, Laborat\u00f3rios Vit\u00f3ria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, and Vifor. SS has received consulting fees from Celltrion, Lilly, Takeda, AbbVie, Merck, Ferring, Pharmacosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, and Tillotts Pharma; has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, Janssen, Merck, Warner Chilcott, and Falk Pharma; and holds research grants from Abbvie, Janssen, Takeda, and Olympus. VS declares speaker\u2019s fees from Pfizer, Tillots, and Giuliani and advisory fees from J&J. S Sidhu is an employee and shareholder of Pfizer Inc. SD has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor. DQ declares no conflict of interest. LPB has received consulting fees from Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Applied Molecular Transport, Arena, Banook, BMS, Celltrion, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Iterative Health, Janssen, Lilly, LifeMine, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign, Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Par\u2019 Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, and Ventyx and lecture fees from Abbvie, Alfasigma, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, and Tillots.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}